
EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing. China Merchants Bank International and Mirae Asset Financial Group led the round.
Source: Press Release
EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing.
EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing. China Merchants Bank International and Mirae Asset Financial Group led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination